Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/750,996 TRANSMITTAL Filing Date December 31, 2003 First Named Inventor **FORM** Antoni KOZLOWSKI Art Unit 1711 **Examiner Name Duc TRUONG** (to be used for all correspondence after initial filing) Attorney Docket Number SHE0065.00 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): PTO/SB/08B; 7 Cited References; and Request for Refund Express Abandonment Request Return Receipt Postcard CD, Number of CD(s) ___ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Nektar Therapeutics Signature Printed name Mark A. Wilson Date Reg. No. 8,2006 43,275 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in arenyelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature 10/18/2006 Date Anna Tran Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

OCT 2 3 2006 & TH

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Antoni KOZLOWSKI et al.)	Atty. Docket No.: SHE0065.00
)	Examiner: Duc TRUONG
Application No.: 10/750,996))	Group Art Unit: 1711
Filed: 12/31/2003))	
Title: MALEAMIC ACID POLYMER)	
DERIVATIVES AND THEIR)	
BIOCONJUGATES)	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria Virginia 22313-1450 on 10/18/2006

Signed: /

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

 \boxtimes

within three months of the filing date of a national application or an RCE; within three months of the date of entry of the national stage as set forth in section 1.491 in an

international application; or before the mailing date of a first Office action on the merits (whichever event occurs last). Attached is Check No. _ in the amount of \$0. Please charge the amount of \$____ to Deposit Account 500348 If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348. Respectfully submitted, **NEKTAR THERAPEUTICS** Jul a. Wilser Dated: 016by 18 2006 By: Reg. No. 43,275 **NEKTAR THERAPEUTICS** 150 Industrial Road

San Carlos, CA 94070 (650) 631-3100

OCT 2 3 2016

Farm PTO/SB/08B (Modified)

Information Disclosure Statement By Applicant

Application No.:

10/750,996

Applicant:

Atty Docket No.:

Antoni KOZLOWSKI et al.

Filing Date:

Group:

(Use Several Sheets if Necessary)

12/31/2003

SHE0065.00

1711

Other Documents

	1	
Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	A	NEKTAR [™] - Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, pp. 1-20, (Catalog – 2003).
	В	NOF CORPORATION, "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals", pp. 1-46, (Catalogue 2003-1 st).
	С	NOF CORPORATION, "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals", pp. 1-50, (Catalogue 2003-2 nd).
	D	SHEARWATER POLYMERS, INC., p. 2-49, (Catalog - March, 1995).
	E	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives, pp. 1-53, (Catalog – July, 1997).
	F	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, pp. 1-50, (Catalog - 2000).
	G	SHEARWATER CORPORATION, Polyethylene Glycol and Derivatives for Biomedical Applications, pp.1-17, (Catalog – 2001).
Examiner:	.1	Date Considered:

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.